相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Infectious Diseases
Lucia Graziani et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Medicine, General & Internal
Federico Baldi et al.
Summary: COVID-19 in immunocompromised patients is difficult to treat, and the understanding of SARS-CoV-2 interaction with the host immune system and therapy role is limited. The use of monoclonal antibodies and antiviral combinations for viral replication and disease progression is lacking data. Here, we report successful treatment of two COVID-19 patients with positive SARS-CoV-2 RNAemia, who had undergone rituximab treatment for non-Hodgkin lymphoma and granulomatosis with polyangiitis, respectively, using a salvage combination therapy with sotrovimab, remdesivir, and nirmatrelvir/ritonavir.
FRONTIERS IN MEDICINE
(2023)
Letter
Immunology
Ola Blennow et al.
CLINICAL INFECTIOUS DISEASES
(2023)
Editorial Material
Immunology
Caitlin A. Trottier et al.
Summary: The management of patients with prolonged viral shedding and COVID-19 symptoms is still unclear. This study presents a case of successful treatment of a patient with persistent, symptomatic severe acute respiratory syndrome coronavirus 2 infection and associated organizing pneumonia using an extended course of combination antiviral therapy.
CLINICAL INFECTIOUS DISEASES
(2023)
Editorial Material
Infectious Diseases
Ana Belkin et al.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Immunology
Emily S. Ford et al.
Summary: This case study describes a patient with B-cell ALL and SARS-CoV-2 who experienced persistent pneumonia and viremia despite various treatments, but achieved full recovery with a combination therapy of nirmatrelvir/ritonavir and remdesivir.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Cecilia Bonazzetti et al.
Summary: The relationship between antibody response (AbR) and breakthrough infection (BI) after SARS-CoV-2 vaccination in 614 solid organ transplant (SOT) recipients was analyzed. Heart transplant recipients had the lowest probability of immunization and the highest probability of breakthrough infection. Non-high-level AbR and shorter time from transplantation were associated with breakthrough infection.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Infectious Diseases
David Luque-Paz et al.
Summary: This article summarizes the impact of COVID-19 in patients treated for B-cell malignancy or receiving CAR-T cell therapy. Preventive vaccination is essential for these immunosuppressed patients, and the best available treatments are passive immunotherapy and direct-acting antiviral drugs. Larger trials are needed to assess COVID-19 therapeutics in B-cell depleted populations.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Allergy
Li-An K. Brown et al.
Summary: This study characterized a cohort of patients with chronic or relapsing COVID-19 disease who have immunodeficiency. The findings suggest that remdesivir monotherapy is often ineffective, but the combination of remdesivir with antibody-based therapeutics shows promise.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Jing Sun et al.
Summary: The study revealed that full vaccination was associated with reduced risk of COVID-19 breakthrough infection, regardless of the immune status of patients. Despite full vaccination, persons with immune dysfunction had substantially higher risk for COVID-19 breakthrough infection than those without such a condition. Continued use of nonpharmaceutical interventions (eg, mask wearing) and alternative vaccine strategies (eg, additional doses or immunogenicity testing) are recommended for persons with immune dysfunction after full vaccination.
JAMA INTERNAL MEDICINE
(2022)
Letter
Medicine, General & Internal
Emi Takashita et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Biotechnology & Applied Microbiology
Mahrokh Marzi et al.
Summary: This work reports the discovery and description of PF-07321332, a major oral SARS-CoV-2 protease inhibitor, with in vitro human coronavirus antiviral activity and excellent off-target and in vivo immune profiles. It also introduces the development of a new oral antiviral drug called nirmatrelvir by Pfizer, and provides information on the ongoing phase III clinical trial of the combination of ritonavir and nirmatrelvir.
BIOMED RESEARCH INTERNATIONAL
(2022)
Article
Immunology
Mario A. Martinez et al.
Summary: This article reports a case of successful treatment of a 5-month persistent COVID-19 infection in an immunocompromised patient with 30 consecutive days of remdesivir. Prolonged remdesivir infusion with concurrent cycle threshold monitoring might provide a potential solution for the treatment of difficult-to-treat infections.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Review
Immunology
Susan DeWolf et al.
Summary: Immunocompromised individuals, especially those with hematologic malignancies, are at higher risk of SARS-CoV-2-related diseases and death due to immune deficiencies. Understanding the progression of viral infections in these individuals is crucial and can help improve prevention and treatment strategies for COVID-19.
Article
Virology
Sarah Cook et al.
Summary: Feline infectious peritonitis (FIP) is a fatal disease of cats that currently lacks effective vaccines or treatments. This study aimed to determine and compare the antiviral efficacies of several drugs in vitro and evaluate their pharmacokinetic properties. The results showed that certain drug combinations exhibited synergy against FIPV, the causative agent of FIP.
Article
Infectious Diseases
Alessandra D'Abramo et al.
Summary: Prolonged B-cell depletion caused by anti-CD20 therapy impairs the adaptive immune response, leading to severe manifestations during COVID-19. Two patients under anti-CD20 therapy experienced prolonged and severe COVID-19 but were successfully treated with mAbs targeting the SARS-CoV-2 spike proteins.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Benjamin Israelow et al.
Summary: Research demonstrates that both humoral and cellular immunity play a role in clearing SARS-CoV-2, and convalescent mice or mice vaccinated with mRNA are protected from infection with both the wild type virus and the B.1.351 variant. This protection is mainly mediated by antibody response rather than cellular immunity.
SCIENCE IMMUNOLOGY
(2021)
Letter
Medicine, General & Internal
Teresa Aydillo et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
